Sanmed Snares ￥300M in Series B Financing

(VCBeat) Apr. 02, 2021 -- Recently, Zhuhai Sanmed Biotech Inc. ("Sanmed") announced the completion of the signing with SDIC & China Merchants Investment of 300 million yuan in the Series B financing. The fund raised will be used to facilitate the commercialization and the R&D of liquid biopsy-related technologies for multi-cancer. The joining of SDIC & China Merchants Investment will also support the optimization and integration of resources in the industrial chain and accelerate the development of Sanmed.

Sanmed was co-invested in March 2016 by Cynvenio Biosystems of the United States and Zhuhai Livzon Diagnostics Inc., the first high-tech subsidiary of the listed company, Livzon Pharmaceutical Group. 

Sanmed is a precision medical innovation company that masters the world's advanced tumor liquid biopsy technology, and is committed to providing tumor patients with a world-leading comprehensive liquid biopsy detection guidance program. Currently, Sanmed has two core technologies: LiquidBiopsy rare cell enrichment and separation, and MDA TEST lung nodule benign and malignant differential diagnosis. LiquidBiopsy is a circulating tumor cell enrichment and separation platform that can directly dock with downstream molecular detection. MDA TEST technology is a leading technology for early screening of lung cancer using circulating abnormal cells (CAC).

Sanmed Biotech has integrated global advanced medical technology resources and established a Sino-US dual R&D center. The Chinese team was approved by the Zhuhai Innovation Team in 2018 and has now obtained more than 30 patent applications and authorizations. At the same time, it also builds a mature and stable production quality system team and an experienced medical research and marketing team. At present, the product has been clinically applied in more than 10 top foreign hospitals.

SDIC & China Merchants Investment focuses on investment in the advanced manufacturing industry. It mainly invests in intelligent manufacturing, new energy intelligent vehicles, life science, information and communication technology and other fields. The company is committed to promoting the green, digital and service-oriented development of the manufacturing industry. The team has an AUM of more than 100 billion yuan, with investors including financial institutions, social security funds, state-owned and private capital.